Menarini Asia-Pacific has entered a 10-year exclusive partnership with Pharmacosmos to bring Cosela® (trilaciclib), a first-in-class oncology supportive care therapy, to the Asia-Pacific region. This collaboration excludes China and India and is set to address chemotherapy-induced myelosuppression (CIM), a significant side effect for patients with extensive-stage small cell lung cancer.
Cosela® is designed to protect bone marrow from CIM, a condition that compromises the production of healthy blood cells and can disrupt cancer treatment. Already approved by the FDA, Cosela® is marketed in the US and China, with registration underway in Europe. The first launch in the Asia-Pacific is anticipated in Hong Kong in 2028, followed by Singapore and Thailand in 2029, with other markets such as Australia to follow.
Glen Godresse, CEO of Menarini Asia-Pacific, stated, “Cosela® represents an important advancement in oncology supportive care and the kind of innovation that can make a meaningful difference for patients.” Klaus Abel, Vice President of Global Commercial Partnerships at Pharmacosmos, added, “Menarini Asia-Pacific’s deep local market expertise and patient-focused approach make them the ideal partner.”
The partnership builds on a previous agreement between the two companies to commercialise Monofer®, an innovative iron infusion, across key Asia-Pacific markets. This collaboration underscores Menarini’s commitment to expanding access to innovative therapies in the region, leveraging its comprehensive capabilities from registration to patient access.
